Skip to content

Study · Non-randomized trial · 1995

3 results

The hypotonic effect of intranasal and intravenous glucagon in gastrointestinal radiology.

Pacchioni M, Orena C, Panizza P, Cucchi E, Del Maschio A, Pontiroli AE

Abdominal imaging1 Jan 1995Cited by 9 (Europe PMC)

PMID7894298 (opens in a new tab)DOI10.1007/bf00199643 (opens in a new tab)PepBankPUB-07894298
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients undergoing stomach radiology, intranasal glucagon significantly increased gastric hypomotility compared with placebo.

    In plain wordsIn patients undergoing stomach radiology, intranasal glucagon reduced stomach movement more than placebo.

    Peptide
    Glucagon
    Outcome
    IncreaseGastric hypomotility
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    We found a statistically significant difference between placebo and intranasal or intravenous glucagon in inducing gastric hypomotility, with no significant differences between IN and IV glucagon.
    1 context sentence
    Summary · context
    In the present study, following a double-blind, double placebo protocol vs. placebo, we compared the hypotonic effect of intranasal and intravenous glucagon during a double-contrast barium meal examination of the stomach.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients undergoing stomach radiology, intravenous glucagon significantly increased gastric hypomotility compared with placebo.

    In plain wordsIn patients undergoing stomach radiology, intravenous glucagon reduced stomach movement more than placebo.

    Peptide
    Glucagon
    Outcome
    IncreaseGastric hypomotility
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    We found a statistically significant difference between placebo and intranasal or intravenous glucagon in inducing gastric hypomotility, with no significant differences between IN and IV glucagon.
    1 context sentence
    Summary · context
    In the present study, following a double-blind, double placebo protocol vs. placebo, we compared the hypotonic effect of intranasal and intravenous glucagon during a double-contrast barium meal examination of the stomach.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients undergoing stomach radiology, gastric hypomotility did not differ significantly between intranasal and intravenous glucagon.

    In plain wordsIn patients undergoing stomach radiology, stomach movement did not differ significantly between intranasal and intravenous glucagon.

    Peptide
    Glucagon
    Outcome
    No significant changeGastric hypomotility
    Study

    n: not reported in source

    Comparator
    Intravenous glucagon
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    We found a statistically significant difference between placebo and intranasal or intravenous glucagon in inducing gastric hypomotility, with no significant differences between IN and IV glucagon.
    1 context sentence
    Summary · context
    In the present study, following a double-blind, double placebo protocol vs. placebo, we compared the hypotonic effect of intranasal and intravenous glucagon during a double-contrast barium meal examination of the stomach.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.